Intellia Therapeutics Inc. (NASDAQ: NTLA), a Cambridge, Massachusetts–based CRISPR gene-editing biotechnology company, is experiencing elevated short-selling activity, with approximately 45.3 million shares sold short as of the Jan. 30, 2026 settlement date. That figure represents roughly 40% to 44% of the company’s public float, reflecting an increase from the prior reporting period. With shares trading in the high-$11 range in mid-February 2026 and a market capitalization between approximately $1.37 billion and $1.42 billion, the company sits among mid-cap biotech issuers where concentrated short positioning can contribute to heightened trading volatility.
The elevated short interest, coupled with a days-to-cover ratio ranging from roughly six to 17 depending on the source, underscores the extent of bearish positioning surrounding the stock. Operating within the gene-editing biotechnology sector, Intellia continues to navigate clinical development and regulatory milestones, and sustained short exposure at these levels may intensify price swings during periods of market sensitivity.
To learn more, read the full Economic Sentinel article at https://ibn.fm/t5ml3
Receive IBN News Alerts – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN News Alerts, please visit https://IBN.fm/connected
About Economic Sentinel
Economic Sentinel, in partnership with IBN and USO.live, provides issuers with robust protection against market manipulation, particularly naked shorting, which introduces synthetic shares, depresses stock prices, reduces shareholder value, and jeopardizes company stability. C-level executives at affected issuers: if hedge funds, dark pools, chat rooms, and brokers are impacting your market cap through spoofing, disinformation campaigns, failures to deliver (FTDs), or DTC over-issuances, we equip you with Arbiter AI—our advanced proprietary system that identifies naked shorts, uncovers participants, and compiles comprehensive evidence dossiers for submission to the SEC, FINRA, DOJ, and state regulators. We execute targeted responses, including investigative exposés and referrals to press outlets for syndication, resolving issues in days rather than years, preventing costly class-action lawsuits, facilitating short covers, and recovering significant valuation to strengthen your position. Backed by a proven track record through our four-phase process and continuous monitoring, we guarantee effective results to mitigate shorts, ensure market fairness, and support stock appreciation.
For more information, visit www.EconomicSentinel.com
About IBN
IBN consists of financial brands introduced to the investment public over the course of 20+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.
Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]